Fundraising Fox
Endeavor Biomedicines
San Diego, US · Founded 2018 · Delaware corporation · 52 employees on LinkedIn · 3 known investors
Find your way into Endeavor Biomedicines
Sign up to see every warm intro you have to Endeavor Biomedicines
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Endeavor Biomedicines team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.
Founders & leadership
Endeavor Biomedicines was founded in 2018 by John Hood.
Board
Investors · 3
How we know: the company's own site · Not right? Tell us
How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$221.7M disclosed across 2 rounds · 2022–2024
▶$132.6MraisedMay 2024 · 32 investors · BiotechnologyRule 506(b)
- Patrick G. EnrightDirector
- Bernard DavitianDirector
- John HoodExecutive Officer, Director
- Vishaal TurakhiaExecutive Officer
- Chris KruegerExecutive Officer
- Enoch KariukiExecutive Officer
- Karan TakharDirector
- Miguel de los RiosExecutive Officer
- Monal MehtaDirector
- Wing Cheong LamDirector
- Offering amount
- $132.6M
- Amount sold
- $132.6M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$89.1MraisedFeb 2022 · 16 investors · BiotechnologyRule 506(b)
- Wing Cheong LamDirector
- Bernard DavitianDirector
- Raghu SaripalliExecutive Officer
- John HoodDirector, Executive Officer
- Monal MehtaDirector
- Patrick G. EnrightDirector
- Miguel de los RiosExecutive Officer
- Offering amount
- $101M
- Amount sold
- $89.1M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Endeavor Biomedicines went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Endeavor Biomedicines.
In the news
Frequently asked questions
- What does Endeavor Biomedicines do?
- Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.
- Who founded Endeavor Biomedicines?
- Endeavor Biomedicines was founded by John Hood in 2018.
- Who are Endeavor Biomedicines's investors?
- Endeavor Biomedicines's investors include Fidelity Investments, Longitude Capital, Omega Funds.
- How much funding has Endeavor Biomedicines raised?
- Endeavor Biomedicines has disclosed $221.7M raised across 2 rounds.
- Where is Endeavor Biomedicines headquartered?
- Endeavor Biomedicines is headquartered in San Diego, US.